Related Experiment Video
Updated: May 8, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Synthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells
Babu V Sajesh1, Melanie Bailey, Zelda Lichtensztejn
1Manitoba Institute of Cell Biology and Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada.
Abstract:
Synthetic lethality is a rational approach to identify candidate drug targets for selective killing of cancer cells harboring somatic mutations that cause chromosome instability (CIN). To identify a set of the most highly connected synthetic lethal partner genes in yeast for subsequent testing in mammalian cells, we used the entire set of 692 yeast CIN genes to query the genome-wide synthetic lethal datasets. Hierarchical clustering revealed a highly connected set of synthetic lethal partners of yeast genes whose human orthologs are somatically mutated in colorectal cancer. Testing of a small matrix of synthetic lethal gene pairs in mammalian cells suggested that members of a pathway that remove reactive oxygen species that cause DNA damage would be excellent candidates for further testing. We show that the synthetic lethal interaction between budding yeast rad54 and sod1 is conserved within a human colorectal cancer context. Specifically, we demonstrate RAD54B-deficient cells are selectively killed relative to controls via siRNA-based silencing and chemical inhibition and further demonstrate that this interaction is conserved in an unrelated cell type. We further show that the DNA double strand breaks, resulting from increased reactive oxygen species following SOD1 inhibition, persist within the RAD54B-deficient cells and result in apoptosis. Collectively, these data identify SOD1 as a novel candidate cancer drug target and suggest that SOD1 inhibition may have broad-spectrum applicability in a variety of tumor types exhibiting RAD54B deficiencies.
Insights
Synthetic lethality identifies SOD1 as a novel cancer drug target. Inhibiting SOD1 selectively kills RAD54B-deficient cancer cells by causing persistent DNA damage and apoptosis.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Synthetic lethality offers a strategy for targeted cancer therapy by exploiting genetic vulnerabilities.
- Chromosome instability (CIN) is a hallmark of many cancers, presenting potential targets for synthetic lethality approaches.
Purpose of the Study:
- To identify synthetic lethal partners of yeast CIN genes for potential cancer drug targets.
- To validate the conserved synthetic lethal interaction between RAD54B and SOD1 in human colorectal cancer cells.
Main Methods:
- Genome-wide synthetic lethal datasets in yeast were queried using CIN genes.
- Hierarchical clustering identified highly connected synthetic lethal partners.
- Mammalian cell experiments validated the RAD54B-SOD1 synthetic lethal interaction using siRNA and chemical inhibition.
Main Results:
- A subset of synthetic lethal partners linked to colorectal cancer mutations was identified.
- The synthetic lethal interaction between yeast rad54 and sod1 was conserved in human cells.
- SOD1 inhibition in RAD54B-deficient cells led to increased reactive oxygen species, DNA double-strand breaks, and apoptosis.
Conclusions:
- SOD1 is a promising candidate drug target for cancers with RAD54B deficiencies.
- Targeting SOD1 may offer broad-spectrum therapeutic applicability in various tumor types.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
In-vitro Mutagenesis

